MLM Ranks

Medifast Q1 2025 Financial Results Reported

Medifast (NYSE: MED), the parent company of the habit-based lifestyle program OPTAVIA®, has announced its Q1 2025 financial results, revealing a year marked by transformation, coach support investment, and long-term growth planning. The Medifast Q1 2025 financial results reflect the company’s evolving strategy in a competitive health and wellness market.

Key Highlights – Medifast Q1 2025 Financial Results

  • Revenue: $115.7 million (down 33.8% from Q1 2024)

  • Active earning OPTAVIA coaches: 25,400 (down 32.8%)

  • Revenue per coach: $4,556

  • Net loss: $0.8 million (includes a $0.4 million gain from LifeMD investment)

  • Loss per share: $0.07

  • Cash and investments: $164.6 million

  • Debt: None

Dan Chard - CEO of Medifast

Medifast CEO Emphasizes Strategic Reset and Coach Empowerment

Dan Chard, CEO of Medifast, explained the company’s current focus:

“Today’s consumers want more than weight loss—they want a full lifestyle transformation. Yet 83% don’t feel confident sustaining it. OPTAVIA is designed to meet this need through proven plans and dedicated coaching.”

In response to shifting market behavior, Medifast is prioritizing the revitalization of its coach and customer base with enhanced tools, new product development, and data-driven strategies.

Revenue Trends and Coach Productivity

The decrease in Medifast Q1 2025 financial results was mainly attributed to a smaller number of active earning OPTAVIA coaches. However, average revenue per coach saw only a marginal dip, highlighting growing productivity among newer cohorts.

  • Q1 2024: $174.7 million in revenue with 37,800 coaches

  • Q1 2025: $115.7 million with 25,400 coaches

  • Revenue per coach: relatively stable at $4,556 (vs. $4,623 in Q1 2024)

Profitability and Gross Margin Insights

  • Gross profit: $84.2 million (down from $127.3 million)

  • Gross margin: consistent at 72.8% year-over-year

  • Net loss: $0.8 million or $0.07 per share

The inclusion of a $0.4 million unrealized gain from Medifast’s LifeMD (Nasdaq: LFMD) investment helped offset part of the reported loss.

Forward Outlook for Q2 2025

For the second quarter of 2025, Medifast expects revenue between $85 million and $105 million, with projected loss per share ranging from $0.00 to $0.55, excluding gains or losses from LifeMD investment changes.

This outlook underscores Medifast’s cautious yet optimistic stance as it realigns operations for sustained performance.

About Medifast and OPTAVIA

Medifast is a 40+ year veteran in the health and wellness industry. Through OPTAVIA, it provides a comprehensive lifestyle solution focused on healthy habits, community, personalized coaching, and nutrition.

  • Personalized coaching support

  • Access to GLP-1 medications via LifeMD® when clinically appropriate

  • Emphasis on long-term habit formation and sustainable wellness

Medifast’s mission: “Lifelong Transformation, Making a Healthy Lifestyle Second Nature™”

 Learn more at medifastinc.com

Reviews:

There are no reviews yet. Be the first one to write one.

Leave Your Review Here: